# The potential of ribonucleotide reductase M2 as a novel prognostic maker and therapeutic target to inhibit medulloblastoma proliferation, migration, and invasiveness

## TL;DR

This study shows that high RRM2 levels in medulloblastoma are linked to poor outcomes and that reducing RRM2 can slow tumor growth and spread.

## Contribution

This is the first study to demonstrate RRM2's oncogenic role in medulloblastoma and its potential as a therapeutic target.

## Key findings

- High RRM2 expression in medulloblastoma is associated with poor patient prognosis.
- Knocking down RRM2 inhibits tumor cell proliferation, migration, and invasion in vitro.
- RRM2 overexpression is observed in both WNT and non-WNT/non-SHH medulloblastoma subtypes.

## Abstract

The crucial role of ribonucleotide reductase M2 (RRM2) enzyme in cancer occurrence and progression has been well‐established, but its specific function and significance in medulloblastoma (MB) remains largely unknown. First, we conducted a bioinformatics analysis of public genomic databases and observed highly expressed RRM2 in MB and an association of high RRM2 expression with adverse outcomes. In addition, by collecting clinical MB specimens for polymerase chain reaction (PCR), western blotting (WB), and immunohistochemistry (IHC), RRM2 was confirmed to be highly expressed in tumor tissues. Furthermore, immunohistochemical analysis linked adverse prognosis to high RRM2 expression. Moreover, knocking down RRM2 significantly inhibited MB cell proliferation, migration, and invasion in vitro. This report is the first to demonstrate the oncogenic role of RRM2 in MB, associated with adverse patient outcomes. Knocking down RRM2 contributes to weakened proliferating, migrating, and invading potentials of MB cells. RRM2 is expected to be a novel prognostic biomarker and therapeutic target for MB.

The expression level of RRM2 is significantly higher in medulloblastoma tissues than in normal tissues. High expression predicts poor prognosis in patients with medulloblastoma of the transcriptomic profiles wingless (WNT) and non‐WNT/non‐sonic hedgehog (SHH) subtypes. Knocking down RRM2 in DAOY and ONS76 cells markedly inhibited cell proliferation, migration, and invasiveness.